Vault Nano Inc. Announces Granting of U.S. Cancer Immune Therapy Patent Supporting ImmunOncologyTM Programs and Treatment for Lung and Metastatic Cancers

Share Article

Vault Nano Inc. (http://www.vaultnano.com) announced that it has been granted a U.S. patent titled Vault Complexes for Cytokine Delivery. This patent supports Vault Nano’s ImmunOncologyTM portfolio, a group of new medicines activating specific responses of the immune system to destroy cancer.

Los Angeles, California: Vault Nano Inc. (VNI), a biotechnology company developing vault medicines, was granted U.S. patent Vault Complexes for Cytokine Delivery. This patent is part of a multi-patent family protecting VNI’s cytokine-based immune therapy strategy for treating cancer. Discovered by the Rome Laboratory at UCLA, the ImmunOncologyTM portfolio is based on a novel human protein nanoparticle, called a vault. VNI’s therapies are poised to make a clinical impact in multiple metastatic cancers.

The patent is part of an extensive intellectual property portfolio licensed from the University of California Los Angeles and developed by Vault Nano. “UCLA is a terrific partner for Vault Nano”, said Oliver Foellmer, VNI’s Chief Operating Officer. “Our ongoing development of the vault technology is strongly supported by strategic collaborations of Vault Nano with multiple laboratories at the university.”

Vault Nano is focused on changing the treatment paradigm in cancer. VNI’s ImmunOncologyTM portfolio is based on the unique ability of vault particles to present active payloads to the immune system. “This effect enhances the action of our active ingredient to recruit and educate immune cells to the tumor,” said Professor Leonard Rome. “Vaults really are a unique nanoparticle in that they are inherently a human particle that remains bio-invisible while delivering therapeutic messages to the immune system. Our therapeutic, VNI-101, rallies the patients’ own defenses against the tumor anywhere in the body.” VNI-101 is currently being prepared for clinical testing against late stage lung cancer at UCLA’s Jonsson Comprehensive Cancer Center (JCCC) and for the initiation of human clinical safety testing by the end of 2015.

VNI-101 will initially be tested in patients with stage IV non small cell lung carcinoma and will ultimately be applied to melanoma and other metastatic cancers. The drug will be the cornerstone of multiple anti-cancer immune therapies being developed by the company that promise to be highly effective, while simultaneously reducing the long-term toxicity associated with today’s chemotherapeutics. VNI-101 is part of a pharmaceutical industry movement of immune modulating drugs making their way toward the cancer market. “Immune Oncology is a hot area today and will grow significantly in the coming years,” said Michael Laznicka, VNI Chairman and CEO. “The most exciting aspect of our ImmunOncologyTM approach is that it is highly synergistic with pharmaceutical checkpoint inhibitor programs. We envision that by combining our vault medicines with other immune therapy approaches we will be able to lower dose-dependent side effects and enhance effectiveness to the point where a discussion of short-term survival can transition to one of curative long-term health.”

About Vault Nano Inc.
Vault Nano Inc., located in Los Angeles, California, is the leading biotechnology company in developing and commercializing Vault Medicines. VNI’s mission is to develop safe and effective immunotherapeutics with the goal of changing the existing treatment paradigm of life-threatening and debilitating diseases.

Activating the Immune System to Destroy Cancer
Immune Medicine Powered by Vaults

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Oliver Foellmer
Vault Nano Inc.
since: 01/2015
Like >
Visit website